Summaries for patients. The cost-effectiveness of aspirin, statins, or both drugs in the primary prevention of heart disease.
D001241:Aspirin / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D003198:Computer Simulation; D003327:Coronary Disease / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics* / Q000627:therapeutic use*; D008297:Male; D008390:Markov Chains; D008875:Middle Aged; D011322:Primary Prevention; D019057:Quality-Adjusted Life Years; D012307:Risk Factors; D012680:Sensitivity and Specificity; D020521:Stroke / Q000139:chemically induced
D005343:Fibrinolytic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D001241:Aspirin